BERKELEY, Calif. and
BOSTON, Sept. 2, 2021 /PRNewswire/ -- Cambium
Biomaterials ("Cambium"), the company creating high-performance
biomaterials, today announced a partnership with Ginkgo Bioworks,
Inc. ("Ginkgo"), which is building the leading horizontal platform
for cell programming. Ginkgo, which recently announced a business
combination with Soaring Eagle Acquisition Corp. (Nasdaq: SRNG),
serves customers across industries seeking to develop new and
better products using biology. The partnership will leverage
Ginkgo's Codebase and high-throughput facility to accelerate
Cambium's discovery, development, manufacturing and
commercialization of biomaterials that deliver superior performance
and sustainability across a range of industries.
Cambium designs new functional biomaterials and composites for
use in diverse and extreme environments. Cambium will work with
Ginkgo to explore a diverse set of bio-based molecules and develop
a library of bio-building blocks to support the manufacture of
innovative biomaterial end products, with the initial focus on
materials that provide enhanced heat, flame, laser and sensor
protection. By enabling the design of organisms that can produce
valuable biological products, Ginkgo helps accelerate the
development of innovative, bio-based solutions to the world's most
pressing environmental challenges. This partnership deepens
Ginkgo's involvement in the biomaterials space following the launch
of recent cell programs with other leading biomaterials
companies.
"Cambium is redefining biomaterials by creating high-performance
products that deliver step changes in performance and
sustainability to industries as diverse as aerospace and renewable
energy," said Simon Waddington, CEO
and co-founder at Cambium. "We are excited to work with Ginkgo to
not only expand the universe of these materials but also explore
how to make them biologically. We expect this partnership to grow
our pipeline and accelerate our commercialization timeline."
"Ginkgo helps companies across industries use synthetic biology
to produce better, more sustainable products," said Jason Kelly, CEO at Ginkgo Bioworks. "Product
developers across the spectrum are looking for sustainable
alternatives to petrochemical-based materials to achieve unmet
performance needs. Biomaterials are proving to be even
higher-performing than petrochemical-based alternatives, and we are
excited to support startups like Cambium as they grow and bring
next-gen biomaterials to market."
About Ginkgo Bioworks
Ginkgo is building a platform to
enable customers to program cells as easily as we can program
computers. The company's platform is enabling biotechnology
applications across diverse markets, from food and agriculture to
industrial chemicals to pharmaceuticals. Ginkgo has also actively
supported a number of COVID-19 response efforts, including K-12
pooled testing, vaccine manufacturing optimization and therapeutics
discovery. In May 2021, Ginkgo
announced a business combination with Soaring Eagle Acquisition
Corp. (Nasdaq: SRNG), which, if completed, will result in Ginkgo,
through a parent entity, Ginkgo Bioworks Holdings, Inc., becoming a
public company. The transaction is expected to close in the third
quarter of 2021, subject to regulatory and shareholder approvals,
and other customary closing conditions. For more information, visit
www.ginkgobioworks.com.
MEDIA CONTACT:
press@ginkgobioworks.com
INVESTOR CONTACTS:
investors@ginkgobioworks.com
About Cambium:
Cambium is a San Francisco Bay Area-based company leading
the discovery, development and rapid uptake of end-use products
enabled with high-performance biomaterials. By leveraging its deep
domain expertise, and the convergence of synthetic biology,
materials science, computation and automation, Cambium is advancing
applications based on new high-performance biomaterials that solve
important real-world problems in demanding applications that can't
be solved by currently available materials — across the spectrum
from aerospace to EVs to defense. For more information go to
cambiomat.com.
ADDITIONAL LEGAL INFORMATION
Forward-Looking Statements Legend of Ginkgo
This document contains certain forward-looking statements within
the meaning of the U.S. federal securities laws with respect to the
proposed transaction between Ginkgo and Soaring Eagle, including
statements regarding the benefits of the transaction, the
anticipated timing of the transaction, the services offered by
Ginkgo and the markets in which it operates, and Ginkgo's projected
future results. These forward-looking statements generally are
identified by the words "believe," "project," "expect,"
"anticipate," "estimate," "intend," "strategy," "future,"
"potential," "opportunity," "plan," "may," "should," "will,"
"would," "will be," "will continue," "will likely result," and
similar expressions. Forward-looking statements are predictions,
projections and other statements about future events that are based
on current expectations and assumptions and, as a result, are
subject to risks and uncertainties. Many factors could cause actual
future events to differ materially from the forward-looking
statements in this document, including but not limited to: (i) the
risk that the transaction may not be completed in a timely manner
or at all, which may adversely affect the price of Soaring Eagle's
securities, (ii) the risk that the transaction may not be completed
by Soaring Eagle's business combination deadline and the potential
failure to obtain an extension of the business combination deadline
if sought by Soaring Eagle, (iii) the failure to satisfy the
conditions to the consummation of the transaction, including the
adoption of the agreement and plan of merger by the shareholders of
Soaring Eagle and Ginkgo, the satisfaction of the minimum trust
account amount following redemptions by Soaring Eagle's public
shareholders and the receipt of certain governmental and regulatory
approvals, (iv) the lack of a third party valuation in determining
whether or not to pursue the proposed transaction, (v) the
occurrence of any event, change or other circumstance that could
give rise to the termination of the agreement and plan of merger,
(vi) the effect of the announcement or pendency of the transaction
on Ginkgo business relationships, performance, and business
generally, (vii) risks that the proposed transaction disrupts
current plans of Ginkgo and potential difficulties in Ginkgo
employee retention as a result of the proposed transaction, (viii)
the outcome of any legal proceedings that may be instituted against
Ginkgo or against Soaring Eagle related to the agreement and plan
of merger or the proposed transaction, (ix) the ability to maintain
the listing of Soaring Eagle's securities on Nasdaq, (x) volatility
in the price of Soaring Eagle's securities due to a variety of
factors, including changes in the competitive and highly regulated
industries in which Ginkgo plans to operate, variations in
performance across competitors, changes in laws and regulations
affecting Ginkgo's business and changes in the combined capital
structure, (xi) the ability to implement business plans, forecasts,
and other expectations after the completion of the proposed
transaction, and identify and realize additional opportunities, and
(xii) the risk of downturns in demand for products using synthetic
biology. The foregoing list of factors is not exhaustive. You
should carefully consider the foregoing factors and the other risks
and uncertainties described in the "Risk Factors'' section of
Soaring Eagle's proxy statement/prospectus relating to the
transaction, and in Soaring Eagle's other filings with the SEC.
Soaring Eagle and Ginkgo caution that the foregoing list of factors
is not exclusive. Soaring Eagle and Ginkgo caution readers not to
place undue reliance upon any forward-looking statements, which
speak only as of the date made. Neither Soaring Eagle nor Ginkgo
undertake or accept any obligation or undertaking to release
publicly any updates or revisions to any forward-looking statements
to reflect any change in its expectations or any change in events,
conditions or circumstances on which any such statement is
based.
Additional Information and Where to Find It
This document relates to a proposed transaction between Ginkgo
and Soaring Eagle. This document does not constitute an offer to
sell or exchange, or the solicitation of an offer to buy or
exchange, any securities, nor shall there be any sale of securities
in any jurisdiction in which such offer, sale or exchange would be
unlawful prior to registration or qualification under the
securities laws of any such jurisdiction. In connection with the
proposed transaction, Soaring Eagle filed a proxy statement on
August 13, 2021. The proxy statement
has been sent to all Soaring Eagle shareholders of record as of the
close of business on August 10, 2021.
Soaring Eagle also will file other documents regarding the proposed
transaction with the SEC. Before making any voting decision,
investors and security holders of Soaring Eagle and Ginkgo are
urged to read the registration statement, the proxy
statement/prospectus and all other relevant documents filed or that
will be filed with the SEC in connection with the proposed
transaction as they become available because they will contain
important information about the proposed transaction.
Investors and security holders may obtain free copies of the
proxy statement/prospectus and all other relevant documents filed
or that will be filed with the SEC by Soaring Eagle through the
website maintained by the SEC at www.sec.gov. In addition, the
documents filed by Soaring Eagle may be obtained free of charge by
written request to Soaring Eagle at 955 Fifth Avenue, New York, NY, 10075, Attention: Eli Baker, Chief Financial Officer, (310)
209-7280.
Participants in Solicitation
Soaring Eagle's and Ginkgo and their respective directors and
officers may be deemed to be participants in the solicitation of
proxies from Soaring Eagle's shareholders in connection with the
proposed transaction. Information about Soaring Eagle's directors
and executive officers and their ownership of Soaring Eagle's
securities is set forth in Soaring Eagle's filings with the SEC. To
the extent that holdings of Soaring Eagle's securities have changed
since the amounts printed in Soaring Eagle's proxy statement, such
changes have been or will be reflected on Statements of Change in
Ownership on Form 4 filed with the SEC. Additional information
regarding the interests of those persons and other persons who may
be deemed participants in the proposed transaction may be obtained
by reading the proxy statement/prospectus regarding the proposed
transaction when it becomes available. You may obtain free copies
of these documents as described in the preceding paragraph.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/cambium-biomaterials-announces-partnership-with-ginkgo-bioworks-to-accelerate-industrial-adoption-of-high-performance-biomaterials-301368080.html
SOURCE Ginkgo Bioworks
